Thymidine phosphorylase Inhibitors
1 drugsAbout Thymidine phosphorylase
Thymidine phosphorylase (TP), also known as platelet-derived endothelial cell growth factor (PDECGF), is an enzyme that catalyzes the reversible conversion of thymidine to thymine and 2-deoxy-alpha-D-ribose-1-phosphate. It plays a role in nucleotide metabolism and angiogenesis.
TP is a therapeutic target in oncology, where inhibiting it can disrupt nucleotide metabolism in cancer cells. Currently, there is no genetic evidence data available linking thymidine phosphorylase to specific diseases.
LONSURF is the only FDA-approved drug targeting TP, developed by TAIHO ONCOLOGY and approved in 2015. It is a small molecule used in oncology, with three indications.
Top Thymidine phosphorylase Drugs
TAIHO ONCOLOGY is the only company with an approved drug targeting thymidine phosphorylase.
High market concentration indicates potential entry barriers and limited competition.
Thymidine phosphorylase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Thymidine phosphorylase, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches.
Thymidine phosphorylase Clinical Trials 99 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Thymidine phosphorylase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 34 | 10 | 3 | 21 | 77% |
| Phase 2 | 46 | 10 | 6 | 27 | 63% |
| Phase 3 | 19 | 6 | 2 | 11 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Thymidine phosphorylase Drug Approval Timeline (2015 - 2015)
LONSURF was the first and most recent drug approved in 2015, representing a 1-year span.
The single approval suggests a potentially unsaturated market with room for new entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 71 (28 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Thymidine phosphorylase. A trial counts if an approved drug acting on Thymidine phosphorylase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.